New study reveals Bioiberica's Dermial® delivers superior benefits for skin health

Barcelona, 26 May, 2022 – A new study presented in the recent Experimental Biology Congress (Philadelphia, 2-5 April) concludes that Bioiberica’s Dermial^® ingredient – the first hyaluronic acid matrix ingredient for skin & beauty – delivers superior results for skin health over standard      hyaluronic acid (HA), a popular ingredient in the nutricosmetic industry. Enabled by Dermial^®’s unique composition, these findings present an exciting opportunity for developers looking to innovate in the space and unlock beauty-from-within with a novel and efficacious science-backed solution.

Comprising three naturally-occurring components – HA (60-75%), glycosaminoglycans, including dermatan and chondroitin sulfate, (≥10%) and collagen (≥5%) – Dermial^® brings powerful anti-aging, regenerative and moisturising properties to help maintain the health and nutrition of skin.

To determine the efficacy of Dermial^® versus standard HA – a widely studied molecule, well-recognised for its anti-aging benefits – the study explored its effects compared to standard HA from fermentation (HA-F) and extraction (HA-E) origins.^[1] Factors including type I collagen production, HDF (human dermal fibroblasts) cell proliferation and HEK (human epidermal keratinocytes) cell migration were evaluated following oral supplementation of Dermial^®, HA-F and HA-E. The in-vitro study found that Dermial^® supplementation:

• Significantly stimulated the synthesis of type I collagen by 48.04% ± 11.49, a unique effect not observed with HA-F and HA-E supplementation
• Supported cell proliferation of HDF cells at 24 hours, reaching a rate of 1.18% ± 27, which was significantly higher than rates observed with HA-F and HA-E
• Increased the migration of HEK cells by 102.77% ± 40.86, unlike HA-F and HA-E.

A cutting-edge product that nourishes, hydrates and replenish the skin

These data reveal that Dermial^® has a superior effect on inducing the synthesis of type I collagen, cell proliferation of HDF and cell migration of HEK, compared to standard HA from either fermentation or extraction origin. This indicates that Dermial^® brings powerful regenerative activity to the dermis and epidermis layers of the skin, and supports the maintenance and functionality of the dermis better than standard HA.

“These latest findings build on a growing bank of pre-clinical evidence highlighting the important benefits of Dermial^® for skin health,” comments Daniel Martínez Puig, Head of R&D Human Health, Bioiberica. “Previous studies have revealed the ingredient’s mechanism of action, ability to be absorbed in the body and safety when taken orally. But now, we can also confirm that Dermial^® offers greater efficacy compared to standard HA – a highly sought ingredient in the nutricosmetic market, by both formulators and consumers alike. In addition, it is effective at a low dose of 60 mg/day and has excellent organoleptic properties, as well as Novel Food (EU Commission) and GRAS status (FDA).”

“The skin and beauty market is witnessing exponential growth. Consumers are constantly seeking new ingredients and products to enable them to live full, healthy lives – including looking after their skin health by combatting the effects of pollution, sun damage, stress and more,” says Jaume Reguant, Healthcare Director at Bioiberica. “Dermial^® is a HA solution with a difference – helping manufacturers breathe new life into their innovation pipelines and create cutting-edge products that nourish, hydrate and replenish skin.”

Helping customers leverage new opportunities in a busy marketplace, Bioiberica launched its newest solution for the nutricosmetics space, Dermial^®, at Vitafoods Europe, 10-12 May 2022.

To discover new possibilities with Dermial^®, visit: www.bioiberica.com.